Boston Scientific (BSX) | Financial Analysis & Statements

Boston Scientific Corporation | Large-cap | Healthcare

101,49 US$

1,75 %

| Boston Scientific Stock Comparison:

Boston Scientific vs Abbott Laboratories Boston Scientific vs Stryker Boston Scientific vs Medtronic plc Boston Scientific vs Edwards Lifesciences Boston Scientific vs Dexcom Boston Scientific vs S&P 500 | Market

Overview Income Statement Balance Sheet Cash Flow Key Ratios Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 16,7B

Gross Profit 11,5B 68,61 %

Operating Income 3,0B 17,93 %

Net Income 1,8B 11,02 %

EPS (Diluted) 1,25 US$

Balance Sheet Metrics

Total Assets 39,4B

Total Liabilities 17,4B

Shareholders Equity 22,0B

Debt to Equity 0,79

Cash Flow Metrics

Operating Cash Flow 3,0B

Free Cash Flow 2,4B

Revenue & Profitability Trend

Income Statement

Metric	2024	2023	2022	2021	2020
Revenue	16,7B	14,2B	12,7B	11,9B	9,9B
Cost of Goods Sold	5,3B	4,3B	4,0B	3,7B	3,5B
Gross Profit	11,5B	9,9B	8,7B	8,2B	6,4B
Operating Expenses	7,6B	6,6B	5,9B	5,6B	5,0B
Operating Income	3,0B	2,4B	2,0B	1,8B	684,0M
Pre-tax Income	2,3B	2,0B	1,1B	1,1B	-79,0M
Income Tax	436,0M	393,0M	443,0M	36,0M	2,0M
Net Income	1,8B	1,6B	698,0M	1,0B	-82,0M
EPS (Diluted)	1,25 US$	1,07 US$	0,45 US$	0,69 US$	-0,12 US$

Income Statement Trend

Balance Sheet

Metric	2024	2023	2022	2021	2020
Assets
Current Assets	6,9B	6,5B	5,8B	6,3B	6,7B
Non-Current Assets	32,5B	28,6B	26,7B	25,9B	24,1B
Total Assets	39,4B	35,1B	32,5B	32,2B	30,8B
Liabilities
Current Liabilities	6,4B	4,9B	3,8B	4,3B	3,7B
Non-Current Liabilities	11,0B	10,7B	11,1B	11,3B	11,8B
Total Liabilities	17,4B	15,6B	14,9B	15,6B	15,5B
Equity
Total Shareholders Equity	22,0B	19,5B	17,6B	16,6B	15,3B

Balance Sheet Composition

Cash Flow Statement

Metric	2024	2023	2022	2021	2020
Operating Activities
Net Income	1,8B	1,6B	698,0M	1,0B	-82,0M
Operating Cash Flow	3,0B	2,4B	1,2B	1,8B	1,2B
Investing Activities
Capital Expenditures	-787,0M	-707,0M	-576,0M	-540,0M	-364,0M
Investing Cash Flow	-5,4B	-2,5B	-2,1B	-2,0B	-411,0M
Financing Activities
Dividends Paid	0	-28,0M	-55,0M	-55,0M	-28,0M
Financing Cash Flow	1,2B	-125,0M	2,4B	-155,0M	-5,3B
Free Cash Flow	2,4B	1,7B	914,0M	1,3B	1,1B

Cash Flow Trend

Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 72,80

Forward P/E 35,75

Price to Book 6,64

Price to Sales 8,41

PEG Ratio 35,75

Profitability Ratios

Profit Margin 11,58 %

Operating Margin 20,09 %

Return on Equity 9,50 %

Return on Assets 5,28 %

Financial Health

Current Ratio 1,45

Debt to Equity 52,16

Beta 0,69

Per Share Data

EPS (TTM) 1,37 US$

Book Value per Share 15,02 US$

Revenue per Share 11,91 US$

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
bsx	147,6B	72,80	6,64	9,50 %	11,58 %	52,16
Abbott Laboratories	232,9B	17,38	4,77	30,65 %	31,89 %	27,09
Stryker	144,2B	50,99	6,89	14,26 %	12,31 %	82,92
Medtronic plc	111,9B	24,17	2,33	9,51 %	13,90 %	59,09
Edwards Lifesciences	44,1B	31,05	4,35	16,51 %	75,71 %	6,86
Dexcom	32,1B	61,65	14,18	23,72 %	12,90 %	113,97

Financial data is updated regularly. All figures are in the company's reporting currency.